vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

Riley Exploration Permian, Inc. is the larger business by last-quarter revenue ($113.9M vs $75.1M, roughly 1.5× MEDIFAST INC). On growth, Riley Exploration Permian, Inc. posted the faster year-over-year revenue change (11.2% vs -36.9%). Riley Exploration Permian, Inc. produced more free cash flow last quarter ($24.6M vs $-6.6M). Over the past eight quarters, Riley Exploration Permian, Inc.'s revenue compounded faster (3.9% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

MED vs REPX — Head-to-Head

Bigger by revenue
REPX
REPX
1.5× larger
REPX
$113.9M
$75.1M
MED
Growing faster (revenue YoY)
REPX
REPX
+48.0% gap
REPX
11.2%
-36.9%
MED
More free cash flow
REPX
REPX
$31.2M more FCF
REPX
$24.6M
$-6.6M
MED
Faster 2-yr revenue CAGR
REPX
REPX
Annualised
REPX
3.9%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MED
MED
REPX
REPX
Revenue
$75.1M
$113.9M
Net Profit
$-70.4M
Gross Margin
69.4%
Operating Margin
-10.4%
38.3%
Net Margin
-61.8%
Revenue YoY
-36.9%
11.2%
Net Profit YoY
EPS (diluted)
$-1.64
$-3.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
REPX
REPX
Q1 26
$113.9M
Q4 25
$75.1M
$97.3M
Q3 25
$89.4M
$106.9M
Q2 25
$105.6M
$85.4M
Q1 25
$115.7M
$102.5M
Q4 24
$119.0M
$102.7M
Q3 24
$140.2M
$102.3M
Q2 24
$168.6M
$105.4M
Net Profit
MED
MED
REPX
REPX
Q1 26
$-70.4M
Q4 25
Q3 25
$-2.3M
$16.3M
Q2 25
$2.5M
$30.5M
Q1 25
$-772.0K
$28.6M
Q4 24
Q3 24
$1.1M
$25.7M
Q2 24
$-8.2M
$33.5M
Gross Margin
MED
MED
REPX
REPX
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
MED
MED
REPX
REPX
Q1 26
38.3%
Q4 25
-10.4%
26.9%
Q3 25
-4.6%
27.0%
Q2 25
-1.0%
33.7%
Q1 25
-1.1%
48.3%
Q4 24
0.6%
31.2%
Q3 24
1.5%
17.1%
Q2 24
-4.7%
50.9%
Net Margin
MED
MED
REPX
REPX
Q1 26
-61.8%
Q4 25
Q3 25
-2.5%
15.3%
Q2 25
2.3%
35.7%
Q1 25
-0.7%
27.9%
Q4 24
Q3 24
0.8%
25.1%
Q2 24
-4.8%
31.8%
EPS (diluted)
MED
MED
REPX
REPX
Q1 26
$-3.38
Q4 25
$-1.64
$4.02
Q3 25
$-0.21
$0.77
Q2 25
$0.22
$1.44
Q1 25
$-0.07
$1.36
Q4 24
$0.08
$0.52
Q3 24
$0.10
$1.21
Q2 24
$-0.75
$1.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
$240.7M
Stockholders' EquityBook value
$198.9M
$553.4M
Total Assets
$248.0M
$1.2B
Debt / EquityLower = less leverage
0.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
REPX
REPX
Q1 26
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Total Debt
MED
MED
REPX
REPX
Q1 26
$240.7M
Q4 25
$247.9M
Q3 25
$367.0M
Q2 25
$275.2M
Q1 25
$249.3M
Q4 24
$269.5M
Q3 24
$288.6M
Q2 24
$322.7M
Stockholders' Equity
MED
MED
REPX
REPX
Q1 26
$553.4M
Q4 25
$198.9M
$634.2M
Q3 25
$214.7M
$566.5M
Q2 25
$216.0M
$556.9M
Q1 25
$211.0M
$532.4M
Q4 24
$210.1M
$510.6M
Q3 24
$207.3M
$507.4M
Q2 24
$205.3M
$489.0M
Total Assets
MED
MED
REPX
REPX
Q1 26
$1.2B
Q4 25
$248.0M
$1.2B
Q3 25
$268.2M
$1.2B
Q2 25
$269.3M
$1.0B
Q1 25
$280.0M
$994.9M
Q4 24
$284.2M
$993.5M
Q3 24
$291.2M
$997.9M
Q2 24
$293.5M
$1.0B
Debt / Equity
MED
MED
REPX
REPX
Q1 26
0.43×
Q4 25
0.39×
Q3 25
0.65×
Q2 25
0.49×
Q1 25
0.47×
Q4 24
0.53×
Q3 24
0.57×
Q2 24
0.66×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
REPX
REPX
Operating Cash FlowLast quarter
$-5.3M
$47.2M
Free Cash FlowOCF − Capex
$-6.6M
$24.6M
FCF MarginFCF / Revenue
-8.8%
21.6%
Capex IntensityCapex / Revenue
1.8%
41.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
REPX
REPX
Q1 26
$47.2M
Q4 25
$-5.3M
$64.9M
Q3 25
$12.1M
$63.6M
Q2 25
$-3.4M
$33.6M
Q1 25
$3.4M
$50.4M
Q4 24
$-4.9M
$66.4M
Q3 24
$9.1M
$72.1M
Q2 24
$13.1M
$51.6M
Free Cash Flow
MED
MED
REPX
REPX
Q1 26
$24.6M
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
FCF Margin
MED
MED
REPX
REPX
Q1 26
21.6%
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Capex Intensity
MED
MED
REPX
REPX
Q1 26
41.3%
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Cash Conversion
MED
MED
REPX
REPX
Q1 26
Q4 25
Q3 25
3.90×
Q2 25
-1.36×
1.10×
Q1 25
1.76×
Q4 24
Q3 24
8.04×
2.81×
Q2 24
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons